Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dexamethasone
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 22, 2020
Details:
The full results of the large randomised clinical trial released in the New England Journal of Medicine confirmed the benefits for people with advanced or moderate disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Delamanid
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2020
Details:
Deltyba has potent bactericidal activity against Mycobacterium tuberculosis and is the first approved compound from the bicyclic nitro-imidazole derivatives for the treatment of pulmonary MDR-TB in adult patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Influenza HA Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Kitasato Pharmaceutical
Deal Size: Undisclosed Upfront Cash: $3.5 million
Deal Type: Agreement March 27, 2020
Details:
After a review of sales strategy and discussions, the companies have reached an agreement to terminate the cooperative sales agreement for Influenza HA Vaccine.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
